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Traditionally, nephroureterectomy is the gold standard therapy for upper tract recurrence of transitional cell carcinoma
(TCC) following cystectomy and urinary diversion. With advances in endoscopic equipment and improvements in technique,
conservative endourologic management via a retrograde or antegrade approach is technically feasible with acceptable outcomes in
patients with bilateral disease, solitary renal units, chronic renal insuﬃciency, or signiﬁcant medical comorbidities. Contemporary
studies have expanded the utility of these techniques to include low-grade, low-volume disease in patients with a normal
contralateral kidney. The aim of this report is to review the current outcomes of conservative management for upper tract disease
and discuss its application and relevance in patients following cystectomy with lower urinary tract reconstruction.
Copyright © 2009 Jeﬀrey John Tomaszewski et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
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1.Introduction
Upper tract transitional cell carcinoma (UTTCC) represents
5% of all urothelial cancers [1]. Due to the proposed
ﬁeld defect associated with these lesions, removal of the
entire urothelium on the ipsilateral side oﬀers the best
chance of surgical cure. For this reason, the traditional
and gold standard treatment for UTTCC has been radi-
cal nephroureterectomy [2]. However, minimally invasive
endoscopic techniques have been developed to treat patients
with bilateral upper tract disease, poor candidates for radical
surgery, and those with solitary renal units. In more recent
times, even healthy patients with low-grade, noninvasive
tumors have been managed endoscopically, with the under-
standing that some may require radical nephroureterectomy
if UTTCC should recur or progress.
The incidence of upper tract recurrence following radical
cystectomyis low (3–5%), butthere is anincreased incidence
of upper tract recurrence in patients undergoing cystectomy
with a prior history of superﬁcial bladder disease [3]. Treat-
ment of upper tract recurrence following lower urinary tract
reconstruction is challenging, but with recent technological
advances, both ureteroscopic and percutaneous techniques
have been utilized for surveillance and management in
these complex patients. We review the literature in order to
summarize and deﬁne the advantages and disadvantages of
ureteroscopic and percutaneous management of upper tract
TCC following urinary diversion.
2. Discussion
Uppertracttransitionalcellcarcinoma(UTTCC)isrelatively
uncommon, accounting for approximately 5% of all urothe-
lial tumors and 10% of all renal tumors or approximately
3000 cases per year in the United States [4, 5]. The incidence
of upper tract recurrence following radical cystectomy for
urothelial cancer ranges from 2% to 6% [3, 6–11], with the
majority of recurrence in the ﬁrst 3 years [3]. Additionally,
Tran et al. [3] demonstrated that the risk of upper tract
recurrence does not change with time, emphasizing the
critical importance of continued surveillance for UTTCC
following cystectomy. Patients with associated carcinoma in
situ of the bladder or prostatic urethra, recurrent high risk
superﬁcial cancer of the bladder, and tumor multifocality
are at higher risk of ureteral involvement at the time
of cystectomy [3, 12–17]. In the subgroup with ureteral
involvement at the time of cystectomy, tumor recurrence in
theuppertractwasnotedin16–17%[3,16],withtheauthors2 Advances in Urology
concluding that these patients require vigorous follow up
with urine cytology and upper tract surveillance imaging.
Treatment of upper tract recurrence following cystec-
tomy remains a clinical dilemma. Due to improvements in
ﬁberoptic technology and reﬁnement of endoscopic tech-
niques, conservative management of UTTCC has evolved
into a viable treatment alternative with similar eﬃcacy
to that of radical therapy in select patients with non-
invasive and low-grade disease. Indications for uretero-
scopicand/orpercutaneousendoscopicmanagementinclude
patients with a solitary kidney, bilateral disease, renal
insuﬃciency, or patients who would require dialysis after
nephroureterectomy[18–20].However,inrecentseries,min-
imally invasive procedures have increasingly been utilized
in patients with a normal contralateral kidney [21–23].
These studies have concluded that patients who have soli-
tary, small (<1.5cm), low-grade, and completely resectable
tumors are candidates for endoscopic management if they
are willing to accept lifelong surveillance for recurrence
[21, 24].
Surveillance should be lifelong and tailored to the
patient’s tumor grade and stage. Our institution’s surveil-
lance protocol includes urine cytology every three months,
and upper tract imaging (computed tomography urogram,
intravenous pyelogram, or retrograde pyelogram) every six
months for the ﬁrst two years, then yearly thereafter [20,
25, 26]. Contemporary surveillance protocols for upper tract
disease include surveillance ureteroscopy at frequent deﬁned
intervals [26, 27]. In patient’s with lower urinary tract
reconstruction, this may not be feasible and needs to be
tailored to each individual patient. Management of recurrent
upper tract TCC is comparable to that of primary upper
tract TCC and must be adapted to the tumor characteristics
and patient; nephroureterectomy is usually recommended
for recurrences that have evidence of grade and stage
progression.
Adrawbackofendoscopyinthemanagementofpelvical-
iceal lesions is its low sensitivity for the detection of invasive
lesions and thus its low reliability in staging [25, 26, 28].
The correlation between grade and stage of upper tract
tumors has previously been demonstrated, thus many rely
primarily on the grade of the endoscopic biopsy specimen
for pathologic assessment [26, 29]. Abnormal upper tract
urinary cytology results have been shown to predict tumor
recurrence and correlate with pathologic tumor grade and
stage [26, 28, 30].
Surgical resection of a UTTCC following cystectomy
and continent or incontinent urinary diversion presents
a unique challenge. Although such a recurrence portends
an overall poor prognosis, a maximal eﬀort must be
made to resect localized disease. Endoscopic management
of upper tract abnormalities in patients following urinary
diversion is complicated by diﬃcult retrograde access to
the upper collecting system [31]. Although technically
challenging, endoscopic retrograde, percutaneous antegrade
or combined antegrade, and retrograde approaches have
been described [31, 32] and can be utilized in the eval-
uation and treatment of upper tract urothelial cancer
recurrence.
3. Retrograde Ureteroscopic Access
The ureteroscopic approach is typically the least invasive
surgical treatment option for UTTCC. It is also the most
thorough procedure for surveying the entire collecting
system for posttreatment surveillance. Advantages include
limited morbidity in the setting of an outpatient procedure
and the potential oncologic beneﬁt of a closed system [31].
The most challenging aspect of ureteroscopic management
followingbothcontinentandincontinentlowerurinarytract
reconstruction is obtaining retrograde access to the ureter.
In cases following continent diversion, the neobladder
can be accessed via the urethra using rigid or ﬂexible
ureteroscopy [33]. In cases of incontinent urinary diversion,
a ﬂexible cystoscope can be passed through the stoma
into the reservoir. Mucous and debris is often encountered
on initial inspection and must be copiously irrigated to
improve visualization [31]. A cystogram or loopogram
under ﬂuoroscopic guidance can be performed to help
delineating the aﬀerent limb and the ureteral anastomosis.
Administration of methylene blue or indigo carmine may
aid in the identiﬁcation of the ureteral anastamoses. Upon
identiﬁcation, the ureteral oriﬁces can be cannulated with
guidewires or open-ended ureteral access catheters. The use
of contrast to clearly delineate anatomic landmarks can
also facilitate a combined antegrade/retrograde approach in
select mid-ureteral tumors that may require dual access for
complete resection. In select cases ureteral access sheaths can
help to facilitate repeated passes of the ureteroscope and
tumor basketing. In addition, the use of an access sheath
decreases irrigation pressure [34] and may theoretically
reduce the possibility of pyelolymphatic backﬂow and tumor
dissemination. Baskets or biopsy forceps can be used for
tumor debulking and biopsy, and electrocautery or laser
ﬁbers can be used to ablate tumor and control hemorrhage
[33].Disadvantagesincludepotentialstagingerrors,inability
to treat large lesions in a single setting, and diﬃculty in
accessing lower pole lesions [35].
Although minimally invasive treatment methods were
originally developed for patients that could not undergo
open surgery, the ureteroscopic approach to UTTCC has
been shown to be an eﬃcacious ﬁrst-line treatment to
address UTTCC of low stage and grade [35]. Ureteroscopy
provides adequate access for biopsy under direct vision, and
mechanical, ablative, or laser removal of papillary lesions
anywherealongtheuppertracturothelium.ChenandBagley
[36] treated 23 patients with UTTCC; 8 remained disease-
free, and 15 had recurrences treated at a mean follow up
of 35 months, with 100% disease-speciﬁc survival. Keeley
et al. [26]a n dM a r t ´ ınez-Pi˜ neiro et al. [19] reported tumor-
free rates of 76% and 71%, respectively, among patients with
low-grade UTTCC. Due to its eﬃcacy, safety, and minimal
morbidity, the ureteroscopic approach is a very attractive
treatment alternative for low-grade urothelial carcinoma
[33].
Nelson et al. [31] reported their experience with retro-
grade ureteroscopy for the management of 13 renal units
in 8 patients following continent neobladder diversion.
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positive cytology, or renal calculi. The ureter and renal
pelvis were successfully accessed and visualized in 76%, and
they were unable to access the ureteral oriﬁces in three
remaining patients. While demonstrating that retrograde
access is technically feasible in this patient population,
attempting to access the collecting system retrograde in
reconstructed patients may have severe consequences. Care
mustbetakentoavoiddamagingthecontinencemechanism,
perforating the reservoir, or disrupting the ureteral-enteric
anastomoses. In our practice, primary ureteroscopic therapy
is considered for upper tract evaluation in patients with
lower urinary tract reconstruction for small ﬁlling defects on
upper tract imaging or positive cytology, with the intention
of treating smalllesions during the initial setting. Allpatients
are counseled that access or treatment failure is a distinct
possibility, and that further antegrade or more deﬁnitive
open or laparoscopic surgical procedures may be warranted.
Complications speciﬁc to ureteroscopic tumor treatment
include extraluminal spillage or propagation of neoplasm,
ureteral perforation, and ureteral stricture formation [22].
The reported stricture rate following ureteroscopic manage-
ment of upper tract TCC has ranged from 5% to 14% [19,
26,37].Whenaureteralstrictureformsfollowingendoscopic
management of upper tract TCC, it is imperative to perform
a biopsy of the region to rule out malignant disease [36].
4. Percutaneous Access
The evolution of lower urinary tract reconstruction has
resulted in a growing number of patients in need of complex
upper tract management. Although technically feasible,
evaluation and treatment of upper tract abnormalities are
complicated by diﬃcult retrograde access to the upper col-
lecting system due to unusual anatomy and lack of anatomic
landmarks [31]. The diﬃculty of accessing both reﬂuxing
and nonreﬂuxing ureterointestinal anastamoses restricts the
use of the size and type of endoscopic equipment necessary
for complete resection of UTTCC which is challenging
from a retrograde approach under ideal circumstances.
Although more invasive, a percutaneous approach avoids
these diﬃculties through direct access and oﬀers a high
success rate with minimal morbidity [32].
The method of obtaining percutaneous access is similar
to what has been described for percutaneous nephrolitho-
tomy. Under ﬂuoroscopic guidance, a direct puncture of the
involved calyx or an upper pole or central calyx puncture for
renal pelvis, lower pole, or ureteral tumors is recommended
[38]. Following tract dilation, a 30Fr access sheath is placed,
and rigid or ﬂexible nephroscopy may be performed. Once
the oﬀending lesion is visualized, frozen section pathology
examinationisrecommendedtoruleoutahigh-gradelesion.
The ideal resection modality depends on tumor size and
type, but monopolar and bipolar cautery, laser, rollerball
electrode, and electrovaporization techniques have been
described. The entire tumor should be ablated and the
base fulgurated or resected. Flexible nephroscopy should be
carried out to ensure that all areas of the kidney are clear
of tumor. A nephrostomy tube should be left in place for
external drainage to preserve access and to facilitate adjuvant
chemotherapy. In select cases, a second look nephroscopy
on postoperative day 1-2 to ensure complete resection is
recommended. In the case of continent cutaneous diversion,
percutaneous access into the pouch under direct vision with
a 10mm trocar has also been described [39]. Historically
utilized in cases of large urinary diversion calculi, this
technique requires cystoscopy through the continent stoma
to achieve percutaneous access under direct vision which
has the potential for damage to the continence mechanism
as well as the development of stomal stenosis and has only
theoretical implications for access to the upper tract.
Smith et al. reported the ﬁrst large series of percutaneous
resectionsofUTTCCinasolitarykidney[40].Theoncologic
eﬃcacy of percutaneous resection has most often been
measured in terms of disease recurrence, which has been
shown to correlate with tumor grade [20, 41–43]. In review
of several large series, recurrence rates for grade 1 (5–20%)
[23, 41–44] and grade 2 diseases (6–33%) [23, 41–45]h a v e
been reported as signiﬁcantly lower than recurrence rates for
grade 3 disease (31–60%) [23, 41–43]. In addition, tumor
grade has been shown to have prognostic signiﬁcance, and
death from low-grade UTTCC is rare [45]. It is important to
note that prognosis for high-grade and high-stage UTTCCs
is poor regardless of treatment modality. In a series of
25 patients undergoing percutaneous resection of grade 3
disease, Liatsikos et al. reported a 56% recurrence rate and
64% disease-speciﬁc survival [43] which is comparable to
series examining ureteroscopic resection and radical therapy.
The major advantages of the percutaneous approach
in patients following urinary diversion are that it allows
direct access and the use of larger endoscopes, improving
visualization. Both rigid and ﬂexible endoscopes can be
passed through the percutaneous tract, facilitating inspec-
tion of the entire calyceal system. The use of larger
instruments facilitates the resection of large lesions, and
makes tumor removal more eﬃcient. The availability of
larger instruments, including resectoscopes, grasping/biopsy
forceps, and laser ﬁbers, minimizes resection time allowing
complete resection of large tumors in a single setting that
would be diﬃcult ureteroscopically [38]. Direct antegrade
access also facilitates access to lower pole calyceal tumors.
Ureteroscopic access and visualization of the lower pole are
limitedbythelossofdeﬂectioncausedbyinstrumentpassage
through the working channel [22]. The additional beneﬁts
of repeat nephroscopy for additional resection and the
delivery of adjuvant therapy are facilitated by a percutaneous
approach. This is of particular advantage in patients with
large (>1cm) tumor burden, solitary kidney, poor renal
function, or signiﬁcant comorbidites that would preclude
open or laparoscopic nephroureterectomy. Bleeding due to
the vascularity of the kidney and proximity to the hilum
[46] and antegrade tract seeding [47] are complications
of percutaneous treatment that despite infrequently being
reported are still of signiﬁcant concern. In comparison to
the retrograde approach, percutaneous resection of upper
tract TCC is more invasive and is associated with higher
complication rates. Major complications of percutaneous
resection include perforation, nephrostomy tract seeding,
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investigators and depends greatly on the size and extent of
the treated lesion as well as ease of access, but transfusion
rates up to 37% have been reported [43].
5. AdjuvantTherapy
A beneﬁcial role for topical adjuvant therapy following the
resection of UTTCC has not been proven in randomized tri-
als. While retrograde instillation of agents into the collecting
system has been described [35, 48], percutaneous resection
with simultaneous nephrostomy tube placement facilitates
antegrade instillation, maximizing chemotherapeutic agent
contact with the urothelium. A disadvantage of retrograde
catheterization, particularly in patients with continent uri-
nary diversion, is that cystoscopy with ureteral catheter
placement must be performed prior to each instillation.
Currently, there is no consensus as to which technique
is more eﬀective. In an initial study comparing outcomes
in patients receiving postresection BCG with those who
did not, Jabbour and Smith reported a signiﬁcantly lower
recurrence rate in patients with grade 1 tumors who received
adjuvant BCG. There was no beneﬁt for patients with grade
2 and grade 3 disease [38]. Rastinehad et al. [49]r e p o r t e d
a 25% decreased likelihood of progression at 65 months
follow up among 24 renal units with low-grade UTTCC
undergoing BCG instillation. Despite the lack of evidence
from randomized trials, the potential beneﬁts and relative
safety of adjuvant therapy provide an attractive alternative in
patients with grade 2 and grade 3 disease in a solitary renal
unit, patients with chronic renal insuﬃciency, or patients
that are poor surgical candidates.
6. Conclusions
Nephroureterectomyisthegoldstandardtreatmentmodality
for high-grade and large-burden upper tract TCC recurrence
following cystectomy and urinary diversion. However, with
technical advances in equipment and increasing facility
with endoscopic techniques, a minimally invasive approach
is feasible in select patients. In the setting of a solitary
kidney, chronic renal insuﬃciency, or signiﬁcant comor-
bidity, preservation of renal function and prevention of
recurrence are paramount. Reports of percutaneous tract
seeding and recurrence due to pyelovenous backﬂow are
uncommon but are a signiﬁcant concern with each modality
of conservative therapy. When choosing a surgical approach
in a patient following lower urinary tract reconstruction,
the ease of access, preservation of renal function, and
oncologic eﬃcacy must all be taken into consideration.
Although technically possible, accessing the lower tract from
a retrograde approach can be diﬃcult and the capability for
complete resection is limited for larger or lower pole lesions.
Although more invasive, a percutaneous approach oﬀers
directaccesswithincreasedvisualization,improvedresection
capability, and acceptable morbidity rates. Experience with
ureteroscopic and percutaneous techniques enables full
access to the reconstructed urinary tract and adds to the
armamentarium of therapeutic options in the management
of upper tract recurrence following cystectomy and urinary
diversion.
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